Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

The High Court ruled on a significant patent dispute involving Pfizer and GSK, addressing costs and confidentiality.

The sale represents nearly 7.7% of issued share capital of Haleon, which was created by the merger of GSK and Pfizer's ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...

Pfizer divests $3.05 billion of Haleon shares, cutting its stake to 7.3% in a strategic shift to refocus on core ...

While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

Pfizer is selling around 700 million ordinary shares in Haleon, reducing its stake from 15% to about 7.3%. This sale follows its earlier reduction of ownership and reflects ongoing pressure from hedge ...

The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from ...

GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early ...

Pfizer has further reduced its holding in Haleon, it was confirmed on Wednesday, after the drugs giant offloaded 700m shares ...

Pfizer is set to raise £2.5bn by selling a 7.7% stake in Haleon, the UK consumer healthcare company, in a block trade on ...